Reduced expression of chemoattractant receptors by polymorphonuclear leukocytes in Hyper IgE Syndrome patients

Immunology Letters

Volumn 130, Issue 1-2, 2010, Pages 97-106

  Mintz, Roni ^a   Garty, Ben Zion ^a,b   Meshel, Tsipi ^a   Marcus, Nufar ^a,b   Katanov, Christina ^a   Cohen Hillel, Efrat ^a   Ben Baruch, Adit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

CXCR1; CXCR2; FPR; Hyper IgE Syndrome (HIES); Polymorphonuclear leukocytes (PMN)

Indexed keywords

CHEMOATTRACTANT; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR6; CHEMOKINE RECEPTOR CXCR7; CHEMOKINE RECEPTOR CXCR8; FORMYLMETHIONYLLEUCYLPHENYLALANINE; FORMYLPEPTIDE RECEPTOR; IMMUNOGLOBULIN E RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ANTIGEN BINDING CELL; ARTICLE; BINDING AFFINITY; CELL ACTIVITY; CELL ADHESION; CELL STIMULATION; CELLULAR DISTRIBUTION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEREGULATION; FEMALE; HUMAN; HYPER IGE SYNDROME; INFLAMMATION; MALE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING;

ADOLESCENT; ADULT; CELL MOVEMENT; CHILD, PRESCHOOL; DOWN-REGULATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; JOB'S SYNDROME; MALE; NEUTROPHILS; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B;

EID: 77950944460     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2009.12.006     Document Type: Article

References (75)

1. Leung D.Y., Geha R.S. Clinical and immunologic aspects of the hyperimmunoglobulin E syndrome. Hematol Oncol Clin North Am 1988, 2:81-100.
2. Donabedian H., Gallin J.I. The hyperimmunoglobulin E recurrent-infection (Job's) syndrome. A review of the NIH experience and the literature. Medicine (Baltimore) 1983, 62:195-208.
3. Grimbacher B., Holland S.M., Puck J.M. Hyper-IgE syndromes. Immunol Rev 2005, 203:244-250.
4. Erlewyn-Lajeunesse M.D. Hyperimmunoglobulin-E syndrome with recurrent infection: a review of current opinion and treatment. Pediatr Allergy Immunol 2000, 11:133-141.
5. Hsu C.T., Lin Y.T., Yang Y.H., Chiang B.L. The hyperimmunoglobulin E syndrome. J Microbiol Immunol Infect 2004, 37:121-123.
6. Lawrence T., Puel A., Reichenbach J., Ku C.L., Chapgier A., Renner E., et al. Autosomal-dominant primary immunodeficiencies. Curr Opin Hematol 2005, 12:22-30.
7. Heimall J., Freeman A., Holland S.M. Pathogenesis of Hyper IgE Syndrome. Clin Rev Allergy Immunol 2009.
8. Grimbacher B., Schaffer A.A., Holland S.M., Davis J., Gallin J.I., Malech H.L., et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet 1999, 65:735-744.
9. Renner E.D., Puck J.M., Holland S.M., Schmitt M., Weiss M., Frosch M., et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr 2004, 144:93-99.
10. Holland S.M., DeLeo F.R., Elloumi H.Z., Hsu A.P., Uzel G., Brodsky N., et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007, 357:1608-1619.
11. Minegishi Y., Saito M., Tsuchiya S., Tsuge I., Takada H., Hara T., et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448:1058-1062.
12. Ma C.S., Chew G.Y., Simpson N., Priyadarshi A., Wong M., Grimbacher B., et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008, 205:1551-1557.
13. Renner E.D., Rylaarsdam S., Anover-Sombke S., Rack A.L., Reichenbach J., Carey J.C., et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol 2008, 122:181-187.
14. Jiao H., Toth B., Erdos M., Fransson I., Rakoczi E., Balogh I., et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol 2008, 46:202-206.
15. Buckley R.H., Sampson H.A., Fisher P.M., Becker W.G., Shirley L.R. Abnormalities in the regulation of human IgE synthesis. Ann Allergy 1982, 49:67-72.
16. Khatib S.A., Keles S., Garcia-Lloret M., Karakoc-Aydiner E., Reisli I., Artac H., et al. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. J Allergy Clin Immunol 2009, 124:342-348.
17. Milner J.D., Brenchley J.M., Laurence A., Freeman A.F., Hill B.J., Elias K.M., et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773-776.
18. Minegishi Y., Saito M., Nagasawa M., Takada H., Hara T., Tsuchiya S., et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 2009, 206:1291-1301.
19. Davis S.D., Schaller J., Wedgwood R.J. Job's syndrome. Recurrent, " cold" , staphylococcal abscesses. Lancet 1966, 1:1013-1015.
20. Hill H.R., Ochs H.D., Quie P.G., Clark R.A., Pabst H.F., Klebanoff S.J., et al. Defect in neutrophil granulocyte chemotaxis in Job's syndrome of recurrent " cold" staphylococcal abscesses. Lancet 1974, 2:617-619.
21. Clark R.A., Root R.K., Kimball H.R., Kirkpatrick C.H. Defective neutrophil chemotaxis and cellular immunity in a child with recurrent infections. Ann Intern Med 1973, 78:515-519.
22. Chikazawa S., Nunoi H., Endo F., Matsuda I., Honda M. Hyperimmunoglobulin-E-associated recurrent infection syndrome accompanied by chemotactic inhibition of polymorphonuclear leukocytes and monocytes. Pediatr Res 1984, 18:365-369.
23. Dahl M.V., Greene W.H., Quie P.G. Infection, dermatitis, increased IgE, and impaired neutrophil chemotaxis. A possible relationship. Arch Dermatol 1976, 112:1387-1390.
24. Fontan G., Lorente F., Garcia Rodriguez M.C., Ojeda J.A. Defective neutrophil chemotaxis and hyperimmunoglobulinemia E-a reversible defect?. Acta Paediatr Scand 1976, 65:509-511.
25. Church J.A., Frenkel L.D., Wright D.G., Bellanti J.A. T lymphocyte dysfunction, hyperimmunoglobulinemia E, recurrent bacterial infections, and defective neutrophil chemotaxis in a Negro child. J Pediatr 1976, 88:982-985.
26. Blum R., Geller G., Fish L.A. Recurrent severe staphylococcal infections, eczematoid rash, extreme elevations of IgE, eosinophilia, and divergent chemotactic responses in two generations. J Pediatr 1977, 90:607-609.
27. Issekutz A.C., Lee K.Y., Biggar W.D. Neutrophil chemotaxis in two patients with recurrent staphylococcal skin infections and hyperimmunoglobulin E. J Lab Clin Med 1978, 92:640-647.
28. Van Scoy R.E., Hill H.R., Ritts R.E., Quie P.G. Familial neutrophil chemotaxis defect, recurrent bacterial infections, mucocutaneous candidiasis, and hyperimmunoglobulinemia E. Ann Intern Med 1975, 82:766-771.
29. Netea M.G., Kullberg B.J., van der Meer J.W. Severely impaired IL-12/IL-18/IFNγ axis in patients with hyper IgE syndrome. Eur J Clin Invest 2005, 35:718-721.
30. Netea M.G., Schneeberger P.M., de Vries E., Kullberg B.J., van der Meer J.W., Koolen M.I. Th1/Th2 cytokine imbalance in a family with hyper-IgE syndrome. Neth J Med 2002, 60:349-353.
31. Chehimi J., Elder M., Greene J., Noroski L., Stiehm E.R., Winkelstein J.A., et al. Cytokine and chemokine dysregulation in hyper-IgE syndrome. Clin Immunol 2001, 100:49-56.
32. Donabedian H., Gallin J.I. Mononuclear cells from patients with the hyperimmunoglobulin E-recurrent infection syndrome produce an inhibitor of leukocyte chemotaxis. J Clin Invest 1982, 69:1155-1163.
33. Donabedian H., Gallin J.I. Two inhibitors of neutrophil chemotaxis are produced by hyperimmunoglobulin E recurrent infection syndrome mononuclear cells exposed to heat-killed staphylococci. Infect Immun 1983, 40:1030-1037.
34. Mackay C.R. Chemokines: immunology's high impact factors. Nat Immunol 2001, 2:95-101.
35. Johnston B., Butcher E.C. Chemokines in rapid leukocyte adhesion triggering and migration. Semin Immunol 2002, 14:83-92.
36. Laudanna C., Kim J.Y., Constantin G., Butcher E. Rapid leukocyte integrin activation by chemokines. Immunol Rev 2002, 186:37-46.
37. Mahalingam S., Karupiah G. Chemokines and chemokine receptors in infectious diseases. Immunol Cell Biol 1999, 77:469-475.
38. Dalpiaz A., Spisani S., Biondi C., Fabbri E., Nalli M., Ferretti M.E. Studies on human neutrophil biological functions by means of formyl-peptide receptor agonists and antagonists. Curr Drug Targets Immune Endocr Metabol Disord 2003, 3:33-42.
39. Guo R.F., Ward P.A. Role of C5a in inflammatory responses. Annu Rev Immunol 2005, 23:821-852.
40. Yang D., Chertov O., Oppenheim J.J. The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cell Mol Life Sci 2001, 58:978-989.
41. Le Y., Murphy P.M., Wang J.M. Formyl-peptide receptors revisited. Trends Immunol 2002, 23:541-548.
42. Boulay F., Rabiet M.J. The chemoattractant receptors FPR and C5aR: same functions-different fates. Traffic 2005, 6:83-86.
43. Selvatici R., Falzarano S., Mollica A., Spisani S. Signal transduction pathways triggered by selective formylpeptide analogues in human neutrophils. Eur J Pharmacol 2006, 534:1-11.
44. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242.
45. Zeilhofer H.U., Schorr W. Role of interleukin-8 in neutrophil signaling. Curr Opin Hematol 2000, 7:178-182.
46. Mukaida N. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 2000, 72:391-398.
47. Baggiolini M., Loetscher P., Moser B. Interleukin-8 and the chemokine family. Int J Immunopharmacol 1995, 17:103-108.
48. Murphy P.M. Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin Hematol 1997, 34:311-318.
49. Chuntharapai A., Kim K.J. Regulation of the expression of IL-8 receptor A/B by IL-8: possible functions of each receptor. J Immunol 1995, 155:2587-2594.
50. Richardson R.M., Pridgen B.C., Haribabu B., Ali H., Snyderman R. Differential cross-regulation of the human chemokine receptors CXCR1 and CXCR2. Evidence for time-dependent signal generation. J Biol Chem 1998, 273:23830-23836.
51. Green S.P., Chuntharapai A., Curnutte J.T. Interleukin-8 (IL-8), melanoma growth-stimulatory activity, and neutrophil-activating peptide selectively mediate priming of the neutrophil NADPH oxidase through the type A or type B IL-8 receptor. J Biol Chem 1996, 271:25400-25405.
52. Feniger-Barish R., Yron I., Meshel T., Matityahu E., Ben-Baruch A. IL-8-induced migratory responses through CXCR1 and CXCR2: association with phosphorylation and cellular redistribution of focal adhesion kinase. Biochemistry 2003, 42:2874-2886.
53. Feniger-Barish R., Ran M., Zaslaver A., Ben-Baruch A. Differential modes of regulation of CXC chemokine-induced internalization and recycling of human CXCR1 and CXCR2. Cytokine 1999, 11:996-1009.
54. Richardson R.M., Ali H., Pridgen B.C., Haribabu B., Snyderman R. Multiple signaling pathways of human interleukin-8 receptor A. Independent regulation by phosphorylation. J Biol Chem 1998, 273:10690-10695.
55. Hammond M.E., Lapointe G.R., Feucht P.H., Hilt S., Gallegos C.A., Gordon C.A., et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol 1995, 155:1428-1433.
56. Van Damme J., Wuyts A., Froyen G., Van Coillie E., Struyf S., Billiau A., et al. Granulocyte chemotactic protein-2 and related CXC chemokines: from gene regulation to receptor usage. J Leukoc Biol 1997, 62:563-569.
57. Zlotnik A., Yoshie O., Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 2006, 7:243.
58. Freeman A.F., Davis J., Anderson V.L., Barson W., Darnell D.N., Puck J.M., et al. Pneumocystis jiroveci infection in patients with hyper-immunoglobulin E syndrome. Pediatrics 2006, 118:e1271-e1275.
59. Stringer J.R., Beard C.B., Miller R.F., Wakefield A.E. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002, 8:891-896.
60. Garty B.Z., Ben-Baruch A., Rolinsky A., Woellner C., Grimbacher B., Marcus N. Pneumocystis jiroveci pneumonia in a baby with hyper-IgE syndrome. Eur J Pediatr 2009, 169:35-37.
61. Diaz G.A. CXCR4 mutations in WHIM syndrome: a misguided immune system?. Immunol Rev 2005, 203:235-243.
62. Reiche E.M., Bonametti A.M., Voltarelli J.C., Morimoto H.K., Watanabe M.A. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr Med Chem 2007, 14:1325-1334.
63. Coelho A., Matos A., Catarino R., Pinto D., Sousa H., Pereira D., et al. The influence of chemokine receptor CCR2 genotypes in the route to cervical carcinogenesis. Gynecol Obstet Invest 2007, 64:208-212.
64. Blanpain C., Libert F., Vassart G., Parmentier M. CCR5 and HIV infection. Receptors Channels 2002, 8:19-31.
65. Panopoulos A.D., Zhang L., Snow J.W., Jones D.M., Smith A.M., El Kasmi K.C., et al. STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood 2006, 108:3682-3690.
66. Burger M., Hartmann T., Burger J.A., Schraufstatter I. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene 2005, 24:2067-2075.
67. Hechtman D.H., Cybulsky M.I., Fuchs H.J., Baker J.B., Gimbrone M.A. Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol 1991, 147:883-892.
68. Jones S.A., Moser B., Thelen M. A comparison of post-receptor signal transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2. Chemokine mediated activation of p42/p44 MAP-kinase (ERK-2). FEBS Lett 1995, 364:211-214.
69. Simonet W.S., Hughes T.M., Nguyen H.Q., Trebasky L.D., Danilenko D.M., Medlock E.S. Long-term impaired neutrophil migration in mice overexpressing human interleukin-8. J Clin Invest 1994, 94:1310-1319.
70. Wiekowski M.T., Chen S.C., Zalamea P., Wilburn B.P., Kinsley D.J., Sharif W.W., et al. Disruption of neutrophil migration in a conditional transgenic model: evidence for CXCR2 desensitization in vivo. J Immunol 2001, 167:7102-7110.
71. Ben-Baruch A., Grimm M., Bengali K., Evans G.A., Chertov O., Wang J.M., et al. The differential ability of IL-8 and neutrophil-activating peptide-2 to induce attenuation of chemotaxis is mediated by their divergent capabilities to phosphorylate CXCR2 (IL-8 receptor B). J Immunol 1997, 158:5927-5933.
72. Follin P., Wymann M.P., Dewald B., Ceska M., Dahlgren C. Human neutrophil migration into skin chambers is associated with production of NAP-1/IL8 and C5a. Eur J Haematol 1991, 47:71-76.
73. Colditz I.G., Movat H.Z. Desensitization of acute inflammatory lesions to chemotaxins and endotoxin. J Immunol 1984, 133:2163-2168.
74. Arraes S.M., Freitas M.S., da Silva S.V., de Paula Neto H.A., Alves-Filho J.C., Auxiliadora Martins M., et al. Impaired neutrophil chemotaxis in sepsis associates with GRK expression and inhibition of actin assembly and tyrosine phosphorylation. Blood 2006, 108:2906-2913.
75. Mueller S.G., White J.R., Schraw W.P., Lam V., Richmond A. Ligand-induced desensitization of the human CXC chemokine receptor-2 is modulated by multiple serine residues in the carboxyl-terminal domain of the receptor. J Biol Chem 1997, 272:8207-8214.